Basal Analog denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for basal analog are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Step Therapy for Basal Analog Insulin

UnitedHealthcare's step therapy protocol for basal analog insulins requires that a patient first try a preferred, typically lower-cost, insulin product before coverage is extended to the prescribed agent. The plan's coverage policy establishes a sequence of preferred products that must be documented as tried and either failed or been found clinically inappropriate before coverage is granted for the step-two medication. A step-therapy denial does not mean the prescribed insulin is wrong — it means the plan requires evidence that the lower-step alternative was addressed first.

## Why This Denial Is Appealable

Many states have step-therapy override laws, and federal guidance permits step-therapy exceptions when the required first-step drug is contraindicated, has already failed, or is otherwise clinically inappropriate for a specific patient. If your prescriber can document that the preferred alternative was tried and failed, is unsuitable due to a patient-specific clinical factor, or that requiring the step creates a health risk, a step-therapy exception appeal is well-founded. Review both UnitedHealthcare's published step-therapy policy and your state's step-therapy override protections.

## Your Federal Appeal Rights

• Internal appeal / step-therapy exception: File within the timeframe in your denial letter. Many insurers have a dedicated step-therapy exception pathway that may be faster than a standard appeal.
• External review (ACA §2719 / ERISA §503): If the internal process fails, an Independent Review Organization can independently review whether the step-therapy requirement is clinically appropriate in your case. The external-review window is approximately four months from final internal denial — verify the deadline on your denial notice.
• Expedited review: If requiring a step drug creates an urgent clinical risk, request expedited review explicitly.

## Documents to Gather

1. Prior treatment history with outcomes — a complete record of every insulin or diabetes medication tried, with start dates, stop dates, doses (from the prescribing record), and clinical outcomes or reasons for discontinuation. 2. Step-drug failure or contraindication documentation — if the preferred step drug was tried and failed or is clinically inappropriate, chart notes documenting that fact are the core of the appeal. 3. Diagnosis and clinical severity — chart notes confirming the diagnosis and clinical context that make the prescribed agent necessary. 4. Prescriber step-therapy exception letter — a signed letter addressing UnitedHealthcare's specific step-therapy criteria and explaining why the exception should be granted for this patient.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's step-therapy criteria and your state's step-therapy override statute (if applicable). Build a compliance table:

| Step-Therapy Requirement | Your Evidence | |---|---| | Preferred step drug tried | [drug name, start date, stop date, outcome] | | Step drug failed or was inappropriate | [chart note, prescriber explanation] | | Prescribed drug is medically necessary at this step | [prescriber letter, clinical rationale] |

A well-documented step-therapy exception appeal — showing the prior step was genuinely addressed — is one of the most consistently successful appeal categories.